Newer Macrolides as Empiric Treatment for Acute Q Fever Infection
- 1 December 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (12) , 3644-6
- https://doi.org/10.1128/aac.45.12.3644-3646.2001
Abstract
The effectiveness of newer macrolides in acute Q fever for 113 patients was recorded. The mean times to defervescence were 2.9 days for doxycycline and 3.3, 3.9, 3.9, and 6.4 days for clarithromycin, roxithromycin, erythromycin, and beta-lactams, respectively (P < 0.01 for macrolides versus beta-lactams). We conclude that macrolides may be an adequate empirical antibiotic therapy for acute Q fever.Keywords
This publication has 17 references indexed in Scilit:
- Acute Q Fever PneumoniaChest, 1998
- The in-vitro anti-rickettsial activity of macrolidesJournal of Antimicrobial Chemotherapy, 1996
- In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycinAntimicrobial Agents and Chemotherapy, 1993
- Erythromycin and the treatment of Coxiella burnetii pneumoniaJournal of Antimicrobial Chemotherapy, 1991
- Q fever in Plymouth, 1972–88: A review with particular reference to neurological manifestationsEpidemiology and Infection, 1990
- Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cellsAntimicrobial Agents and Chemotherapy, 1990
- In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolonesAntimicrobial Agents and Chemotherapy, 1987
- Q Fever in the Basque Country: 1981-1984Clinical Infectious Diseases, 1985
- In vivo response of acute Q fever to erythromycin.Thorax, 1982
- Q fever treated with erythromycin.BMJ, 1979